Energy & Endurance
Humanin
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Mitochondrial Neuroprotective
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10 mg
Dosing window: Anytime
Receptor / target: Mitochondrial Receptors
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 2mg - 5mg twice weekly | Under-researched compared to MOTS-c; dose conservatively. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (Mitochondrial Receptors); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: Humanin's potent anti-apoptotic mechanisms (Bcl-2 upregulation, Bax inhibition, cytochrome c suppression) that protect healthy cells from death are mechanistically identical to the pathways cancer cells exploit to become chemotherapy-resistant; exogenous Humanin may protect tumor cells from apoptosis-inducing therapy. Limited / unverified
- Concurrent cytotoxic chemotherapy: Humanin's anti-apoptotic activity directly opposes the mechanism of action of most chemotherapy agents, which rely on triggering apoptosis in rapidly dividing cells. Limited / unverified
- Known hypersensitivity to Humanin or peptide excipients. Limited / unverified
- Pregnancy: mitochondrial-encoded peptide signaling in fetal development is not characterized; safety not established. Limited / unverified
- Breastfeeding: no data. Limited / unverified
- Pediatric use: no safety data. Limited / unverified
- Severe cardiac arrhythmia: IGF-1 receptor and STAT3 pathway activation by Humanin may affect cardiac electrophysiology at high doses; limited human data. Limited / unverified
Side effects (limited evidence)
- Injection site reactions: redness, soreness, mild swelling at subcutaneous injection site; standard peptide injection response; expected and manageable. Limited / unverified
- Under-documented adverse effects: Humanin has the least human safety data of any compound in Category IV; all side effect characterization derives from animal studies and early-stage human observation; unknown adverse effects may exist that have not yet been documented. Limited / unverified
- Theoretical protection of cancer cells from apoptosis: the mechanistically most significant theoretical adverse effect; Bcl-2 upregulation and Bax inhibition are the same pathways that confer chemotherapy resistance in cancer; not observed as a clinical adverse event but represents the primary safety concern. Limited / unverified
- Mild fatigue: reported anecdotally in early weeks of use; possibly related to mitochondrial membrane signaling adjustments. Limited / unverified
- Mild headache: uncommon; not well characterized. Limited / unverified
- Potential IGF-1 receptor pathway modulation: Humanin signals through the IGF-1 receptor at certain concentrations; theoretical implications for insulin-sensitive conditions warrant monitoring in diabetic subjects. Limited / unverified
- No documented endocrine disruption, receptor desensitization, or hormonal suppression in available preclinical literature. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.